ZA200202181B - Agonists specific for the peripheral cannabinoid receptor. - Google Patents

Agonists specific for the peripheral cannabinoid receptor.

Info

Publication number
ZA200202181B
ZA200202181B ZA200202181A ZA200202181A ZA200202181B ZA 200202181 B ZA200202181 B ZA 200202181B ZA 200202181 A ZA200202181 A ZA 200202181A ZA 200202181 A ZA200202181 A ZA 200202181A ZA 200202181 B ZA200202181 B ZA 200202181B
Authority
ZA
South Africa
Prior art keywords
compounds
activity
specific
peripheral
peripheral cannabinoid
Prior art date
Application number
ZA200202181A
Other languages
English (en)
Inventor
Ester Fride
Aviva Breuer
Lumir Hanus
Susanna Tchilibon
Michal Horowitz
Raphael Mechoulam
Aaron Garzon
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of ZA200202181B publication Critical patent/ZA200202181B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
ZA200202181A 1999-10-31 2002-03-18 Agonists specific for the peripheral cannabinoid receptor. ZA200202181B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL132661A IL132661A (en) 1999-10-31 1999-10-31 Agonists specific for peripheral cannabinoid receptors

Publications (1)

Publication Number Publication Date
ZA200202181B true ZA200202181B (en) 2003-05-28

Family

ID=11073405

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200202181A ZA200202181B (en) 1999-10-31 2002-03-18 Agonists specific for the peripheral cannabinoid receptor.

Country Status (13)

Country Link
US (3) US6864291B1 (xx)
EP (1) EP1244440B1 (xx)
JP (1) JP4231906B2 (xx)
KR (1) KR100770695B1 (xx)
AT (1) ATE286389T1 (xx)
AU (1) AU778149B2 (xx)
CA (1) CA2385928A1 (xx)
DE (1) DE60017287T2 (xx)
HU (1) HUP0203681A3 (xx)
IL (2) IL132661A (xx)
NZ (1) NZ518054A (xx)
WO (1) WO2001032169A1 (xx)
ZA (1) ZA200202181B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
DE69910373T2 (de) 1998-05-04 2004-04-01 The University Of Connecticut, Farmington Analgetische und immunomodulierende cannabinoiden
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
JP2003511469A (ja) 1999-10-18 2003-03-25 ユニバーシティ オブ コネチカット 抹消カンナビノイド受容体（ｃｂ２）選択的配位子
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
JP2004532185A (ja) * 2001-01-26 2004-10-21 ユニバーシティ オブ コネチカット 新規なカンナビミメティックリガンド
US7173027B2 (en) * 2001-01-29 2007-02-06 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
WO2003005960A2 (en) * 2001-07-13 2003-01-23 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
CA2464333C (en) 2001-10-26 2011-07-26 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
TW200407110A (en) 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
WO2003061699A1 (fr) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedes pour affections allergiques
EP1469842A4 (en) * 2002-01-31 2006-04-26 Pharmos Corp BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS
IL150302A (en) * 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
CA2496097A1 (en) 2002-08-23 2004-03-04 University Of Connecticut Keto cannabinoids with therapeutic indications
US20060172019A1 (en) * 2003-03-07 2006-08-03 Ralston Stuart H Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
WO2005123053A2 (en) * 2004-06-22 2005-12-29 Pharmos Limited Use of cb2 receptors agonists for the treatment of huntington’s disease
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
CA2650566A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
WO2008001369A1 (en) * 2006-06-27 2008-01-03 Pharmos Corporation Use of cb2 receptor agonists for promoting neurogenesis
US9763894B2 (en) * 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
WO2008107879A1 (en) * 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel cannabidiol derivatives and their use as anti-inflammatory agents
JP2010540618A (ja) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド 幼児の成長および発達を増大するための内在性カンナビノイド
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2010041253A1 (en) 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions comprising cb receptor agonists, uses thereof and methods for their preparation
US20120277296A1 (en) 2009-07-23 2012-11-01 Sophie Lotersztajn Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease
ITMI20122221A1 (it) 2012-12-21 2014-06-22 C4T S C A R L Nuovi composti del 2,3-diidro-4h-1,3-benzossazin-4-one, metodo per prepararli e forma farmaceutica che li comprende
EP2986587B1 (en) 2013-04-17 2023-11-22 Sharon Anavi-Goffer Cb2 receptor ligands for the treatment of psychiatric disorders
EP2992880A1 (en) * 2014-09-04 2016-03-09 Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau Use of heme oxygenase 1 inducers and cannabinoid 2 receptor or delta-opioid receptor agonists in inflammatory pain
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US11612581B2 (en) 2017-08-09 2023-03-28 Cannibite Bvba Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects
WO2021080648A1 (en) * 2019-10-25 2021-04-29 Gelest Technologies, Inc. Silicon-based cannabidiol derivatives and compositions thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL55274A (en) 1978-08-02 1982-08-31 Yissum Res Dev Co 4-(2,6-dihydroxy-4-(dimethylheptyl)phenyl)substituted 2-pinen-10-ol and pinane derivatives,their preparation and pharmaceutical compositions comprising them
US5434295A (en) 1994-02-07 1995-07-18 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors

Also Published As

Publication number Publication date
JP4231906B2 (ja) 2009-03-04
CA2385928A1 (en) 2001-05-10
DE60017287D1 (de) 2005-02-10
HUP0203681A2 (hu) 2003-04-28
AU1245801A (en) 2001-05-14
HUP0203681A3 (en) 2003-05-28
NZ518054A (en) 2003-10-31
KR100770695B1 (ko) 2007-10-29
US20050165118A1 (en) 2005-07-28
AU778149B2 (en) 2004-11-18
DE60017287T2 (de) 2005-12-08
EP1244440B1 (en) 2005-01-05
US6864291B1 (en) 2005-03-08
US7214716B2 (en) 2007-05-08
EP1244440A4 (en) 2003-05-14
US20020173528A1 (en) 2002-11-21
US6903137B2 (en) 2005-06-07
ATE286389T1 (de) 2005-01-15
IL148796A (en) 2008-11-26
KR20030008208A (ko) 2003-01-24
EP1244440A1 (en) 2002-10-02
IL132661A (en) 2008-11-26
WO2001032169A1 (en) 2001-05-10
JP2004505006A (ja) 2004-02-19
IL132661A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
IL132661A0 (en) Agonists specific for the peripheral cannabinoid receptor
EA200101019A1 (ru) Модуляторы рецепторов глюкокортикоидов
MX2007004936A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1.
WO1999063930A8 (en) Novel angiotensin receptor modulators and their uses
BRPI0410721A (pt) composições farmacêuticas espumáveis e métodos para tratamento de um distúrbio
GB0222495D0 (en) Compounds
MXPA05012011A (es) Uso terapeutico de anticuerpos anti-cs1.
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
PA8493701A1 (es) Compuestos para tratar la obesidad
ATE330967T1 (de) An her2 bindende peptidverbindungen
YU2603A (sh) Nova kombinacija (5ht2) agonista i (5ht6) antagonista serotonina kao farmaceutska kombinacija
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
AR022251A1 (es) Antagonistas de factor de necrosis tumoral y uso de los mismos en endometrosis.
AU1092800A (en) N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
DK1525215T3 (da) Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner
ATE266722T1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
WO2002044141A3 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
DE60014429D1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
WO2002024659A3 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
DK0981363T3 (da) Somatostatinagonister til reduktion af legemsvægt
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
AR020559A1 (es) Compuestos n-oxidos de piridina triciclicos, agonistas de la vasopresina, composicion farmaceutica que los comprende y el uso de los mismos para lamanufactura de un medicamento.
MY120281A (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
WO2002024658A3 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists